info@mail.ucallm.com
From Lipid Accumulation to Inflammatory Plaque Remodeling — Empowering Comprehensive Cardiovascular Disease Discovery with Validated Antibody Solutions
Atherosclerosis is a progressive cardiovascular disorder characterized by lipid accumulation, endothelial dysfunction, chronic inflammation, immune cell activation, and vascular remodeling. The pathological process begins with disturbed lipid metabolism and modified lipoprotein retention, followed by macrophage recruitment, foam cell formation, inflammatory amplification, and plaque development.
Beyond cholesterol deposition itself, atherosclerotic progression is regulated by highly interconnected molecular networks involving:
- Lipoprotein uptake and foam cell formation mechanisms
- Cholesterol efflux and reverse cholesterol transport pathways
- Intracellular lipid storage and metabolic remodeling
- Endothelial dysfunction and vascular inflammatory responses
- Macrophage activation and immunometabolic regulation
- Inflammasome activation and inflammatory cytokine signaling
- Oxidative stress and lipid peroxidation responses
- Autophagy–lysosomal pathways controlling lipid clearance
- Epigenetic and transcriptional regulation of lipid homeostasis
We provide comprehensive antibody solutions for investigating atherosclerosis biology—from lipid uptake and cholesterol metabolism to inflammatory plaque remodeling, vascular dysfunction, and therapeutic target discovery.
Validated antibody solutions enable researchers to characterize:
- Lipoprotein uptake and macrophage foam cell formation
- Cholesterol transport and reverse cholesterol metabolism
- Lipid droplet accumulation and intracellular metabolic adaptation
- Endothelial activation and vascular inflammatory responses
- Macrophage immunometabolic reprogramming
- Plaque instability and extracellular matrix remodeling
- Molecular mechanisms underlying cardiovascular disease progression
Atherosclerosis & Lipid Metabolism Biomarker Antibody Portfolio
—Comprehensive Solutions for Lipid Homeostasis, Foam Cell Formation, Inflammation, and Vascular Remodeling Research
Atherosclerosis develops through coordinated interactions among circulating lipoproteins, vascular cells, immune cells, and intracellular metabolic pathways.
Our validated antibody portfolio targets key molecular regulators involved in:
Research Focus | Representative Biomarkers | Research Applications |
Lipoprotein Uptake & Foam Cell Formation | CD68, CD36, OLR1/LOX-1, MSR1/SR-A1, LGALS3, TREM2 | Characterization of macrophage recruitment, modified lipoprotein uptake, lipid accumulation, and foam-cell-associated phenotypes |
Cholesterol Efflux & Homeostasis | ABCA1, ABCG1, LXRα/NR1H3, SCARB1/SR-BI, APOA1 | Investigation of intracellular cholesterol handling, efflux capacity, and macrophage lipid homeostasis |
Cholesterol Biosynthesis & Regulation | SREBP2, HMGCR, LDLR, PCSK9 | Analysis of cholesterol synthesis, LDL uptake, and intracellular cholesterol feedback regulation |
Fatty Acid & Lipid Biosynthesis | SREBP1, ACACA/ACC1, FASN, SCD1, SOAT1/ACAT1 | Investigation of fatty-acid synthesis, neutral lipid storage, and metabolic remodeling |
Lysosomal Lipid Processing | LIPA/LAL, LAMP1, LAMP2, TFEB | Analysis of lysosomal lipid degradation, cholesterol trafficking, and lysosome-dependent metabolic adaptation |
Systemic Lipoprotein & Triglyceride Metabolism | APOB, LDLR, PCSK9, LPL, APOC3, ANGPTL3, ANGPTL4, ANGPTL8 | Investigation of LDL clearance, triglyceride metabolism, and circulating lipoprotein regulation |
Endothelial Activation & Vascular Dysfunction | PECAM1/CD31, VWF, CDH5/VE-cadherin, VCAM1, ICAM1, SELE/E-selectin, NOS3/eNOS, KLF2 | Characterization of endothelial identity, barrier integrity, leukocyte recruitment, and vascular activation |
Inflammatory Signaling & Inflammasome Activation | NLRP3, PYCARD/ASC, CASP1, IL-1β, IL-18, NF-κB p65, GSDMD | Investigation of lipid-driven inflammation, inflammasome activation, cytokine maturation, and inflammatory cell death |
Macrophage Immunometabolism | CD68, TREM2, LGALS3, SPP1, ARG1, NOS2/iNOS | Characterization of macrophage states, lipid adaptation, inflammatory polarization, and plaque-associated immune remodeling |
Oxidative Stress & Lipid Peroxidation | NRF2, KEAP1, SOD2, HMOX1, GPX4, ACSL4 | Analysis of oxidative stress, lipid peroxidation, redox adaptation, and ferroptosis-related mechanisms |
Autophagy–Lysosomal Regulation | TFEB, LC3B, SQSTM1/p62, LAMP1, LAMP2 | Investigation of autophagy–lysosome regulation and lipid clearance mechanisms |
Extracellular Matrix Remodeling & Plaque Stability | MMP2, MMP9, TIMP1, ACTA2/α-SMA, COL1A1, COL3A1, FN1 | Evaluation of extracellular matrix remodeling, fibrous-cap integrity, and plaque stability |
Intracellular Lipid Storage & Metabolic Remodeling Panel
—Characterizing Lipid Droplet Formation and Metabolic Adaptation in Atherosclerotic Lesions
Intracellular lipid metabolism determines whether macrophages efficiently process cholesterol or transition toward dysfunctional foam cell states.
Key Markers
Target | Function | Research Application |
ACAT1/SOAT1 | Converts free cholesterol into cholesteryl esters for lipid storage | Analysis of cholesterol esterification and foam cell formation |
LIPA/LAL | Hydrolyzes lysosomal cholesteryl esters | Investigation of lysosomal lipid processing |
FABP4 | Intracellular lipid carrier linking lipid overload with inflammation | Characterization of lipid-associated macrophage states |
PLIN2 | Lipid droplet-associated protein regulating neutral lipid storage | Assessment of lipid accumulation |
SREBP2 | Controls cholesterol biosynthesis gene expression | Study of intracellular cholesterol regulation |
ACC1/FASN | Rate-limiting enzymes controlling fatty acid synthesis | Investigation of lipid biosynthetic remodeling |
Lipoprotein Metabolism & Cardiovascular Risk Regulation Panel
—Understanding Systemic Lipid Homeostasis and Therapeutic Target Pathways
Circulating lipid levels are controlled by coordinated regulation of LDL uptake, triglyceride metabolism, and lipoprotein processing.
Target | Biological Role | Research Application |
NLRP3 | Cholesterol crystal-activated inflammasome component | Analysis of inflammatory activation |
ASC/PYCARD | Inflammasome adaptor protein mediating caspase activation | Detection of inflammasome assembly |
Caspase-1 | Processes inflammatory cytokines | Evaluation of inflammasome activity |
IL-1β / IL-18 | Pro-inflammatory cytokines promoting plaque inflammation | Cytokine signaling studies |
GSDMD | Executes pyroptotic inflammatory cell death | Investigation of immune-mediated plaque injury |
NF-κB | Master inflammatory transcription regulator | Analysis of inflammatory signaling pathways |
Featured Atherosclerosis Research Panels
—Integrated Antibody Panels for Lipid Remodeling, Vascular Inflammation, and Cardiovascular Disease Discovery
Atherosclerosis is driven by a complex interplay between lipid accumulation, macrophage dysfunction, chronic inflammation, endothelial activation, and extracellular matrix remodeling.
Comprehensive biomarker profiling enables researchers to dissect the molecular events underlying plaque initiation, progression, instability, and therapeutic response.
Foam Cell Formation & Cholesterol Handling Panel—Decoding Lipid Uptake, Cholesterol Accumulation, and Reverse Cholesterol Transport Mechanisms
Key Markers
CD36 | LOX-1 | SR-A1 | ABCA1 | ABCG1 | LXRα | SR-BI | TREM2 | ApoA-I |
CD68 | LGALS3 |
|
|
|
|
|
|
|
Lipid Metabolism & Macrophage Immunometabolism Panel—Investigating Intracellular Lipid Storage, Metabolic Reprogramming, and Cellular Adaptation
Key Markers
ACAT1 | LIPA | FABP4 | PLIN2 |
SREBP1 | SREBP2 | ACC1 | FASN |
Inflammatory Signaling & Immune Activation Panel—Profiling Lipid-Induced Inflammation, Inflammasome Activation, and Immune Responses
Key Markers
NLRP3 | ASC | Caspase-1 | GSDMD |
IL-1β | IL-18 | TNF-α | IL-6 |
NF-κB p65 | p-NF-κB p65 | STAT3 | p-STAT3 |
Endothelial Dysfunction & Vascular Remodeling Panel—Characterizing Vascular Activation, Leukocyte Recruitment, and Plaque Microenvironment Remodeling
Key Markers
VCAM1 | ICAM1 | E-selectin | VE-cadherin | eNOS |
VEGFA | MMP2 | CD31 | α-SMA | Collagen I |
Metabolic Regulation & Therapeutic Target Panel—Exploring Systemic Lipid Regulation and Drug Discovery Pathways
Key Markers
LDLR | PCSK9 | ANGPTL3 | APOB | ANGPTL8 | LPL | FGF21 | PPARα | AMPKα |
Oxidative Stress & Autophagy Regulation Panel—Understanding Cellular Stress Responses and Lipid Clearance Mechanisms
Key Markers
NRF2 | KEAP1 | SOD2 | HO-1 | GPX4 |
TFEB | LC3B | SQSTM1/p62 | LAMP1 | LAMP2 |
Why Researchers Choose Our Atherosclerosis & Lipid Metabolism Antibody Solutions
Validated Cardiovascular Targets. Comprehensive Lipid Panels. Reliable Mechanistic Insights.
Our antibody portfolio supports complete atherosclerosis research workflows:
Research Challenge | Our Solution |
How can I identify foam cell formation? | CD36, LOX-1, SR-A1, FABP4, PLIN2 lipid accumulation markers |
How can I analyze cholesterol homeostasis? | ABCA1, ABCG1, LXRα, SR-BI reverse cholesterol transport markers |
How can I investigate inflammatory plaque progression? | NLRP3, IL-1β, NF-κB, GSDMD inflammasome pathway solutions |
How can I study vascular dysfunction? | VCAM1, ICAM1, eNOS, VEGFA endothelial activation markers |
How can I evaluate lipid metabolism targets? | LDLR, PCSK9, ANGPTL3, FASN, ACC1 metabolic pathway antibodies |
How can I perform spatial plaque profiling? | Multiplex IF/IHC-compatible cardiovascular biomarker solutions |
Key reference
Peng Kong 1, Zi-Yang Cui (2022). Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022 Apr 22;7(1):131.
2.Yong Zhang, Xiao-Nan Chen(2023). CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA. Cell Death Differ. 2023 Dec;30(12):2462-2476.
Rui-Xiang Zeng, Sha Li (2026). Cholesterol-Inflammation Fusion Hypothesis in Atherosclerosis: An Evolving Paradigm in Pathogenesis and Therapy. JACC Asia. 2026 Mar;6(3):284-296.
Yiyong Tang, Jiadi Liu(2026). Engineered heart-liver axis nanoregulators synergize autophagy activation and systemic metabolic reprogramming against atherosclerosis. Sci Adv. 2026 Jul 31;12(31):eaee3352.
Shanshan Gao, Suet Nee Chen (2025). Unraveling "Hot Phases" of Arrhythmogenic Cardiomyopathy. JACC Basic Transl Sci. 2025 Mar;10(3):381-382.